All In MedTech

Device Trial Radar · NCT07396922

Assessment of Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments

A Randomized, Controlled Study to Evaluate the Efficacy and Safety of the SSMD in Neuromotor Rehabilitation

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 30, 2026

Primary completion

Dec 30, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Motion Informatics LTDNot on our public-company list
Sponsor type
Industry
First posted
Feb 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and performance of the Spatial StimeMD (SSMD) medical device in people with multiple sclerosis (MS). The SSMD device is intended to support patients through a non-invasive stimulation program. The study will assess changes in MS-related symptoms and physical function using clinical assessments and patient-reported outcomes.

Conditions

  • Stroke
  • TBI
  • Spinal Cord Injury
  • Peripheral Nerve Damage

Interventions

  • SSMDDevice

    SSMD device-based therapy delivered in addition to conventional therapy. Participants receive 18 sessions, 30 minutes each, administered 6 sessions per week over 3 weeks.

  • Functional Electrical Stimulation (FES)Device

    Functional electrical stimulation (FES) delivered in addition to conventional therapy. Participants receive 18 sessions, 30 minutes each, administered 6 sessions per week over 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Fugl-Meyer Upper Extremity (FMA-UE) motor scoreTime frame: Baseline to post-treatment (end of treatment, 3 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Polsko-Amerykańskie Kliniki Serca SA, Uzdrowisko Ustroń

    Ustroń, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.